Message #35 From:
NewsBot Date: September 27, 2006 08:10:00 AM
NEOP News CORRECTING and REPLACING Neoprobe to Present at Wall Street Analyst Forum; CFO To Provide Business Update
DUBLIN, Ohio--(BUSINESS WIRE)--Please replace the releasedated September 21, 2006with
the following corrected version due to multiple revisions to the
headline and text.
The corrected release reads:
NEOPROBE TO PRESENT AT WALL STREET ANALYST FORUM; CFO TO PROVIDE
BUSINESS UPDATE
Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative
oncology and cardiovascular surgical and diagnostic products, today
announced that its Vice President, Finance and Chief Financial Officer,
Brent Larson, will present tomorrow, September 28, 2006 at 11:10 a.m.
EDT, during the 17th Annual Wall Street Analyst
Forum to be held at the Princeton Club in New York, NY.
Interested parties can access a live, or archived, internet broadcast of
the presentation at:
Neoprobe is a biomedical company focused on enhancing patient care and
improving patient outcome by meeting the critical intraoperative
diagnostic information needs of physicians and therapeutic treatment
needs of patients. Neoprobe currently markets the neo2000®
line of gamma detection systems that are widely used by cancer surgeons
and is commercializing the Quantix®
line of blood flow measurement products developed by its subsidiary,
Cardiosonix Ltd. In addition, Neoprobe holds significant interests in
the development of related biomedical systems and radiopharmaceutical
agents including Lymphoseek® and RIGScan®
CR. Neoprobe’s subsidiary, Cira Biosciences,
Inc., is also advancing a patient-specific cellular therapy technology
platform called ACT. Neoprobe’s strategy is to
deliver superior growth and shareholder return by maximizing its strong
position in gamma detection technologies and diversifying into new,
synergistic biomedical markets through continued investment and
selective acquisitions. www.neoprobe.com
